Alvotech (ICE: ALVO)
Iceland
· Delayed Price · Currency is ISK
1,645.00
-10.00 (-0.60%)
At close: Dec 20, 2024
Alvotech Revenue
Alvotech had revenue of $102.99M USD in the quarter ending September 30, 2024, with 478.60% growth. This brings the company's revenue in the last twelve months to $393.92M, up 517.92% year-over-year. In the year 2023, Alvotech had annual revenue of $93.38M with 9.84% growth.
Revenue (ttm)
$393.92M
Revenue Growth
+517.92%
P/S Ratio
n/a
Revenue / Employee
$394.31K
Employees
999
Market Cap
500.33B ISK
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 93.38M | 8.37M | 9.84% |
Dec 31, 2022 | 85.02M | 45.33M | 114.23% |
Dec 31, 2021 | 39.68M | -29.77M | -42.86% |
Dec 31, 2020 | 69.45M | -13.23M | -16.00% |
Dec 31, 2019 | 82.68M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Oculis Holding AG | 138.64M |
Marel hf. | 250.20B |
Íslandsbanki hf. | 62.96B |
Arion banki hf. | 61.68B |
Sildarvinnslan Hf. | 43.52B |
Brim hf. | 58.07B |
Hagar hf | 177.12B |
Kvika banki hf. | 15.14B |
Alvotech News
- 4 weeks ago - Alvotech's Position In The Coming Biosimilar Gold Rush - Seeking Alpha
- 5 weeks ago - Alvotech (ALVO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024 - GlobeNewsWire
- 6 weeks ago - European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab) - GlobeNewsWire
- 2 months ago - Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 - GlobeNewsWire
- 2 months ago - Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 - GlobeNewsWire
- 2 months ago - Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) - GlobeNewsWire
- 2 months ago - Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) - GlobeNewsWire